A rationally designed small molecule for identifying an in vivo link between metal-amyloid-? complexes and the pathogenesis of Alzheimer's disease.
Ontology highlight
ABSTRACT: Multiple factors, including amyloid-? (A?), metals, and reactive oxygen species (ROS), are involved in the development of Alzheimer's disease (AD). Metal ions can interact with A? species generating toxic oligomers and ROS in vitro; however, the involvement of metal-A? complexes in AD pathology in vivo remains unclear. To solve this uncertainty, we have developed a chemical tool (L2-b) that specifically targets metal-A? complexes and modulates their reactivity (i.e., metal-A? aggregation, toxic oligomer formation, and ROS production). Through the studies presented herein, we demonstrate that L2-b is able to specifically interact with metal-A? complexes over metal-free A? analogues, redirect metal-A? aggregation into off-pathway, nontoxic less structured A? aggregates, and diminish metal-A?-induced ROS production, overall mitigating metal-A?-triggered toxicity, confirmed by multidisciplinary approaches. L2-b is also verified to enter the brain in vivo with relative metabolic stability. Most importantly, upon treatment of 5XFAD AD mice with L2-b, (i) metal-A? complexes are targeted and modulated in the brain; (ii) amyloid pathology is reduced; and (iii) cognition deficits are significantly improved. To the best of our knowledge, by employing an in vivo chemical tool specifically prepared for investigating metal-A? complexes, we report for the first time experimental evidence that metal-A? complexes are related directly to AD pathogenesis.
SUBMITTER: Beck MW
PROVIDER: S-EPMC5494539 | biostudies-literature | 2015 Mar
REPOSITORIES: biostudies-literature
ACCESS DATA